GSK暂停治疗多发性硬化症实验化合物的人体试验

2013-06-14 佚名 生物360

葛兰素史克(GlaxoSmithKline, GSK)今天宣布,已暂停在人类志愿者身上试验一种治疗多发性硬化症的实验化合物,此前在科学论文中造假的指控导致该公司解雇其在中国的顶级研究员。 这家英国公司表示,正在复核 GSK 2618960 的数据,这是一种处于早期临床试验阶段的化合物,其作用机理在《自然医学》(Nature Medicine)杂志2010年发表的一篇论文中得到阐述。 3 月下旬

葛兰素史克(GlaxoSmithKline, GSK)今天宣布,已暂停在人类志愿者身上试验一种治疗多发性硬化症的实验化合物,此前在科学论文中造假的指控导致该公司解雇其在中国的顶级研究员。

这家英国公司表示,正在复核 GSK 2618960 的数据,这是一种处于早期临床试验阶段的化合物,其作用机理在《自然医学》(Nature Medicine)杂志2010年发表的一篇论文中得到阐述。

3 月下旬收到该文数据造假的举报后,该公司已经解雇了其上海神经免疫学中心的主管臧敬五,接受了另一名研究员的辞职,并对另外三名研究员作出行政停职处理。

根据《自然医学》的政策,该公司正在寻求所有联名作者的授权,以求正式撤销这篇论文,该文基于实验室测试和多发性硬化症患者的血液样本,分析了白介素 7 在引发自体免疫性疾病中的作用。

自称已辞职的文章第一作者刘学斌告诉《自然医学》的博客,数据包括来自健康患者的信息,这些信息被错误分类,原因是“当时我们有点匆忙”。

尽管存在明显的造假,研究还是证实了葛兰素史克和其他医药公司正在研发的这种新药的潜力。

公司表示,尚未决定放弃用这种化合物治疗多发性硬化症的试验,并且在继续研究用其治疗其他自体免疫性疾病的可能性。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982872, encodeId=ad7519828e216, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 17 09:38:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906276, encodeId=fb2b19062e696, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jan 30 02:38:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889567, encodeId=a994188956ed7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Sep 04 02:38:00 CST 2013, time=2013-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513611, encodeId=1fec1513611b5, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Sun Jun 16 00:38:00 CST 2013, time=2013-06-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982872, encodeId=ad7519828e216, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 17 09:38:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906276, encodeId=fb2b19062e696, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jan 30 02:38:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889567, encodeId=a994188956ed7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Sep 04 02:38:00 CST 2013, time=2013-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513611, encodeId=1fec1513611b5, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Sun Jun 16 00:38:00 CST 2013, time=2013-06-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982872, encodeId=ad7519828e216, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 17 09:38:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906276, encodeId=fb2b19062e696, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jan 30 02:38:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889567, encodeId=a994188956ed7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Sep 04 02:38:00 CST 2013, time=2013-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513611, encodeId=1fec1513611b5, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Sun Jun 16 00:38:00 CST 2013, time=2013-06-16, status=1, ipAttribution=)]
    2013-09-04 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1982872, encodeId=ad7519828e216, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 17 09:38:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906276, encodeId=fb2b19062e696, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jan 30 02:38:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889567, encodeId=a994188956ed7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Sep 04 02:38:00 CST 2013, time=2013-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513611, encodeId=1fec1513611b5, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Sun Jun 16 00:38:00 CST 2013, time=2013-06-16, status=1, ipAttribution=)]

相关资讯

臧敬五“造假”事件再起波澜,第-作者声明是内部斗争的结果

声明 本人(刘学彬)以第一作者身份于 2010 年在《Nature Medicine》上发表了有关“白细胞介素7(IL-7)对TH17细胞的存活和扩增作用”一文,但最近却被人恶意抹黑而引起广泛热议。以致 GSK 组成由律师参与的调查组展开调查,对此我声明如下: 1、本人是该文的第一作者,至始至终参与实验设计,指导课题组展开实验活动,负责整理各种数据及完成论文初稿写作。臧敬五先生作为该文的通